Abstract:
:Monomeric IgA has been proposed as an alternative antibody format for cancer therapy. Here, we present our studies on the production, purification and functional evaluation of anti-HER2 IgA antibodies as anti-cancer agents in comparison to the anti-HER2 IgG1 trastuzumab. MALDI-TOF MS analysis showed profound differences in glycosylation traits across the IgA isotypes and cell lines used for production, including sialylation and linkage thereof, fucosylation (both core and antennary) and the abundance of high-mannose type species. Increases in sialylation proved to positively correlate with in vivo plasma half-lives. The polymerization propensity of anti-HER2 IgA2m2 could be suppressed by an 18-aa deletion of the heavy chain tailpiece - coinciding with the loss of high-mannose type N-glycan species - as well as by 2 cysteine to serine mutations at positions 320 and 480. The HER2 F(ab')2-mediated anti-proliferative effect of the IgA2m1 and IgA2m2 subtypes was similar to IgG1, whereas the IgA1 isotype displayed considerably lower potency and efficacy. The Fc-mediated induction of antibody-dependent cell-mediated cytotoxicity (ADCC) using human whole blood ADCC assays did not demonstrate such clear differences between the IgA isotypes. However, the potency of the anti-HER2 IgA antibodies in these ADCC assays was found to be significantly lower than that of trastuzumab. In vivo anti-tumor activity of the anti-HER2 IgA antibodies was compared to that of trastuzumab in a BT-474 breast cancer xenograft model. Multiple dosing and sialylation of the IgA antibodies compensated for the short in vivo half-life of native IgA antibodies in mice compared to a single dose of IgG1. In the case of the IgA2m2 antibody, the resulting high plasma exposure levels were sufficient to cause clear tumor stasis comparable to that observed for trastuzumab at much lower plasma exposure levels.
journal_name
MAbsjournal_title
mAbsauthors
Rouwendal GJ,van der Lee MM,Meyer S,Reiding KR,Schouten J,de Roo G,Egging DF,Leusen JH,Boross P,Wuhrer M,Verheijden GF,Dokter WH,Timmers M,Ubink Rdoi
10.1080/19420862.2015.1102812subject
Has Abstractpub_date
2016-01-01 00:00:00pages
74-86issue
1eissn
1942-0862issn
1942-0870journal_volume
8pub_type
杂志文章相关文献
mAbs文献大全abstract::Colorectal cancer represents the second most common cause of cancer-related death. The human A33 transmembrane glycoprotein is a validated tumor-associated antigen, expressed in 95% of primary and metastatic colorectal cancers. Using phage display technology, we generated a human monoclonal antibody (termed A2) specif...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2020.1714371
更新日期:2020-01-01 00:00:00
abstract::High titer (>10 g/L) monoclonal antibody (mAb) cell culture processes are typically achieved by maintaining high viable cell densities over longer culture durations. A corresponding increase in the solids and sub-micron cellular debris particle levels are also observed. This higher burden of solids (≥15%) and sub-micr...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2015.1007824
更新日期:2015-01-01 00:00:00
abstract::Tremendous knowledge has been gained in the understanding of various modifications of IgG antibodies, driven mainly by the fact that antibodies are one of the most important groups of therapeutic molecules and because of the development of advanced analytical techniques. Recombinant monoclonal antibody (mAb) therapeut...
journal_title:mAbs
pub_type: 杂志文章,评审
doi:10.4161/mabs.29883
更新日期:2014-01-01 00:00:00
abstract::Complex cellular targets such as G protein-coupled receptors (GPCRs), ion channels, and other multi-transmembrane proteins represent a significant challenge for therapeutic antibody discovery, primarily because of poor stability of the target protein upon extraction from cell membranes. To assess whether a limited set...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2020.1755069
更新日期:2020-01-01 00:00:00
abstract::Process intensification has shown great potential to increase productivity and reduce costs in biomanufacturing. This case study describes the evolution of a manufacturing process from a conventional processing scheme at 1000-L scale (Process A, n = 5) to intensified processing schemes at both 1000-L (Process B, n = 8...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2020.1770669
更新日期:2020-01-01 00:00:00
abstract::Ectodomains of target antigens for antibody-based therapies can be shed from the target cell surface and found in sera of patients. Shed ectodomains of therapeutic targets not only pose the risk of sequestering therapeutic antibodies but, in a multimeric form, of triggering T cell activation by bispecific antibodies b...
journal_title:mAbs
pub_type: 杂志文章
doi:10.4161/mabs.3.1.14193
更新日期:2011-01-01 00:00:00
abstract::Monoclonal antibodies (mAb) have become a mainstay in tumor therapy. Clinical responses to mAb therapy, however, are far from optimal, with many patients presenting native or acquired resistance or suboptimal responses to a mAb therapy. MAbs exert antitumor activity through different mechanisms of action and we propos...
journal_title:mAbs
pub_type: 杂志文章,评审
doi:10.4161/mabs.22775
更新日期:2013-01-01 00:00:00
abstract::The development and production of recombinant monoclonal antibodies is well established. Although most of these are IgGs, there is also great interest in producing recombinant IgAs since this isotype plays a critical role in providing immunologic protection at mucosal surfaces. The choice of expression system for prod...
journal_title:mAbs
pub_type: 杂志文章
doi:10.4161/mabs.2.3.11802
更新日期:2010-05-01 00:00:00
abstract::We describe here the identification of a stop codon TAA (Stop) → GAA (Glu) = Stop221E mutation on the light chain of a recombinant IgG1 antibody expressed in a Chinese hamster ovary (CHO) cell line. The extended light chain variants, which were caused by translation beyond the mutated stop codon to the next alternativ...
journal_title:mAbs
pub_type: 杂志文章
doi:10.4161/mabs.22232
更新日期:2012-11-01 00:00:00
abstract::Antibody-drug conjugates (ADCs) that exploit the active metabolite SN-38, which is derived from the popular anticancer drug, irinotecan (a camptothecin that inhibits the nuclear topoisomerase I enzyme, inducing double-stranded DNA breaks during the mitotic S-phase of affected cells), represent a substantial advance in...
journal_title:mAbs
pub_type: 杂志文章,评审
doi:10.1080/19420862.2019.1632115
更新日期:2019-08-01 00:00:00
abstract::While many antibody therapeutics are formulated at low concentration (~10-20 mg/mL) for intravenous administration, high concentration (> 100 mg/mL) formulations may be required for subcutaneous delivery in certain clinical indications. For such high concentration formulations, product color is more apparent due to th...
journal_title:mAbs
pub_type: 杂志文章
doi:10.4161/mabs.28257
更新日期:2014-05-01 00:00:00
abstract::Immunoglobulins and T cell receptors (TCRs) share common sequences and structures. With the goal of creating novel bispecific antibodies (BsAbs), we generated chimeric molecules, denoted IgG_TCRs, where the Fv regions of several antibodies were fused to the constant domains of the α/β TCR. Replacing CH1 with Cα and CL...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2015.1007826
更新日期:2015-01-01 00:00:00
abstract::Currently, almost all FDA approved therapeutic antibodies (except ReoPro, Lucentis and Cimzia which are Fabs), and the vast majority of those in clinical trials are full-size antibodies mostly in IgG1 format of about 150 kDa size. A fundamental problem for such large molecules is their poor penetration into tissues (e...
journal_title:mAbs
pub_type: 杂志文章,评审
doi:10.4161/mabs.1.1.7480
更新日期:2009-01-01 00:00:00
abstract::Patents provide one of the few protections companies can avail themselves of to help protect their therapeutic monoclonal antibody products. Just as the therapeutic monoclonal antibody field is constantly evolving, so too is the legal environment surrounding these inventions. In a series of articles, the general state...
journal_title:mAbs
pub_type: 杂志文章
doi:10.4161/mabs.1.4.8860
更新日期:2009-07-01 00:00:00
abstract::A costimulatory signal is required for the full activation of T cells, in addition to the antigen-specific signal via the T cell receptor. The inducible costimulator, ICOS is one of the costimulatory molecules that play an essential role in this process, particularly in the expansion or the development of effector T c...
journal_title:mAbs
pub_type: 杂志文章
doi:10.4161/mabs.1.5.9633
更新日期:2009-09-01 00:00:00
abstract::Fusion proteins combining oligomeric assemblies of a genetically obtained single-chain (sc) variant of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) with antibodies directed against tumor-associated antigens represent a promising strategy to overcome the limited therapeutic activity of conventional s...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2016.1172163
更新日期:2016-07-01 00:00:00
abstract::The advantages of site-specific over stochastic bioconjugation technologies include homogeneity of product, minimal perturbation of protein structure/function, and - increasingly - the ability to perform structure activity relationship studies at the conjugate level. When selecting the optimal location for site-specif...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2018.1512327
更新日期:2018-11-01 00:00:00
abstract::The plasticity of natural immunoglobulin repertoires can be exploited for the generation of phage display libraries. Secondary lymphoid organs, such as the spleen and the lymph nodes, constitute interesting sources of diversity because they are rich in B cells, part of which can be affinity matured. These organs, howe...
journal_title:mAbs
pub_type: 杂志文章
doi:10.4161/mabs.25592
更新日期:2013-09-01 00:00:00
abstract::Due to their excellent specificity for a single epitope, monoclonal antibodies (mAbs) present a means of influencing the function of cells at the molecular level. In particular they show great promise in the treatment of cancer because they can inhibit cancer cell proliferation, tumor angiogenesis, invasiveness and ma...
journal_title:mAbs
pub_type: 杂志文章,评审
doi:10.4161/mabs.3.5.16089
更新日期:2011-09-01 00:00:00
abstract::There are currently ~25 recombinant full-length IgGs (rIgGs) in the market that have been approved by regulatory agencies as biotherapeutics to treat various human diseases. Most of these are based on IgG1k framework and are either chimeric, humanized or human antibodies manufactured using either Chinese hamster ovary...
journal_title:mAbs
pub_type: 杂志文章
doi:10.4161/mabs.19868
更新日期:2012-05-01 00:00:00
abstract::The Fc glycosylation of therapeutic antibodies is crucial for their effector functions and their behavior in pharmacokinetics and pharmacodynamics. To monitor the Fc glycosylation in bioprocess development and characterization,high-throughput techniques for glycosylation analysis are needed. Here, we describe the deve...
journal_title:mAbs
pub_type: 杂志文章
doi:10.4161/mabs.26712
更新日期:2014-01-01 00:00:00
abstract::Genomic studies have been revolutionized by the use of next generation sequencing (NGS) that delivers huge amounts of sequence information in a short span of time. The number of applications for NGS is rapidly expanding and significantly transforming many areas of life sciences. The field of antibody research and disc...
journal_title:mAbs
pub_type: 杂志文章
doi:10.4161/mabs.3.1.14169
更新日期:2011-01-01 00:00:00
abstract::Hepatitis B virus (HBV) produces large (L), middle (M), and small (S) envelope proteins, alternatively referred to as hepatitis B surface antigen (HBsAg). Currently, yeast-derived S protein serves as the preventive vaccine, while hepatitis B immune globulin (HBIG) concentrated from pooled plasma of vaccine recipients ...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2015.1134409
更新日期:2016-01-01 00:00:00
abstract::Monoclonal antibodies are widely used for the treatment of cancer, inflammatory and infectious diseases and other disorders. Most of the marketed antibodies are monospecific and therefore capable of interacting and interfering with a single target. However, complex diseases are often multifactorial in nature, and invo...
journal_title:mAbs
pub_type: 杂志文章,评审
doi:10.4161/mabs.4.2.19000
更新日期:2012-03-01 00:00:00
abstract::Multivalent mono- or bispecific antibodies are of increasing interest for therapeutic applications, such as efficient receptor clustering and activation, or dual targeting approaches. Here, we present a novel platform for the generation of Ig-like molecules, designated diabody-Ig (Db-Ig). The antigen-binding site of D...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2019.1603024
更新日期:2019-07-01 00:00:00
abstract::The epidermal growth factor receptor (EGFR) is frequently dysregulated in human malignancies and a validated target for cancer therapy. Two monoclonal anti-EGFR antibodies (cetuximab and panitumumab) are approved for clinical use. However, the percentage of patients responding to treatment is low and many patients exp...
journal_title:mAbs
pub_type: 杂志文章
doi:10.4161/mabs.3.6.17955
更新日期:2011-11-01 00:00:00
abstract::Monoclonal antibodies (mAbs) against human proteins are the primary protein capture reagents for basic research, diagnosis, and molecular therapeutics. The 2 most important attributes of mAbs used in all of these applications are their specificity and avidity. While specificity of a mAb raised against a human protein ...
journal_title:mAbs
pub_type: 杂志文章
doi:10.4161/19420862.2014.985919
更新日期:2015-01-01 00:00:00
abstract::Accurate measurement and functional characterization of antibody Fc domain N-linked glycans is critical to successful biosimilar development. Here, we describe the application of methods to accurately quantify and characterize the N-linked glycans of 2 IgG1 biosimilars with effector function activity, and show the pot...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2015.1016692
更新日期:2015-01-01 00:00:00
abstract::Surface and interfacial adsorption of antibody molecules could cause structural unfolding and desorbed molecules could trigger solution aggregation, resulting in the compromise of physical stability. Although antibody adsorption is important and its relevance to many mechanistic processes has been proposed, few techni...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2016.1276141
更新日期:2017-04-01 00:00:00
abstract::Monoclonal antibodies (mAbs) are a burgeoning class of therapeutics, with more than 25 approved in countries worldwide. Novel molecules are entering clinical study at a rate of nearly 40 per year, and the commercial pipeline includes approximately 240 mAb therapeutics in clinical studies that have not yet progressed t...
journal_title:mAbs
pub_type: 杂志文章
doi:10.4161/mabs.2.1.10677
更新日期:2010-01-01 00:00:00